BOSTON — Vibrant Gastro, innovators of a novel FDA-cleared capsule to mitigate chronic constipation, has hired two executive leaders to support the company’s aggressive growth trajectory.
- Doug Maley joins Vibrant as VP of Sales. He has nearly 30 years’ experience in senior commercial leadership with a proven impact as a growth driver. Doug previously served as Business Director at Alnylam Pharmaceuticals, with prior efforts at Flexion Therapeutics, Takeda Pharmaceuticals, Bayer Pharmaceuticals and others. He received his Bachelor of Science from Indiana University Bloomington.
- Mark Olmstead joins Vibrant as VP of Market Access and Reimbursement. He has three decades of experience leading strategy, promoting market access and aligning value-based health care and population health in inpatient hospital and outpatient surgical settings. Mark previously served as Senior Director for Smith+Nephew and has led strategic market access and reimbursement effort for companies including Mölnlycke, US and Johnson & Johnson. He received his MBA from La Salle University and his Bachelor of Science from Eastern Connecticut State University.
“The depth of experience and leadership that Doug and Mark bring to Vibrant is significant,” said Vibrant Gastro CEO John Schellhorn. “We are thrilled to have them join the team and move Vibrant’s technology forward to address an unmet need for patients with chronic constipation.”
Up to 1 in 5 American adults — disproportionately women and people of color — struggle with chronic constipation and existing treatments ruin their quality of life with 60 percent saying the treatments, which cause diarrhea, are worse than the constipation. Recently named as one of the best inventions of 2023 by TIME, Vibrant is a new FDA-cleared drug-free treatment that uses a vibrating capsule to restore the colon’s natural rhythm and put you back in control. Clinical results show Vibrant provides one, two and sometimes three additional complete spontaneous bowel movements weekly, even in severe adult patients, with just 1.2 percent of patients reporting diarrhea. Since Vibrant is not a drug, there are no interactions with other drugs, unlike traditional and prescription laxatives. Learn more at vibrantgastro.com.